Specialty products dominate innovative drug approvals — a trend that looks set to continue.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention
British Journal of Cancer Open Access 04 February 2019
-
Quantitative assessment of the expanding complementarity between public and commercial databases of bioactive compounds
Journal of Cheminformatics Open Access 06 July 2009
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Hughes, B. 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov 7, 107–109 (2008). https://doi.org/10.1038/nrd2514
Issue Date:
DOI: https://doi.org/10.1038/nrd2514
This article is cited by
-
Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention
British Journal of Cancer (2019)
-
Isolation and Characterization of a New Antimicrobial Peptide from Pimpinella anisum Seeds
Chemistry of Natural Compounds (2019)
-
Unraveling the autoimmune translational research process layer by layer
Nature Medicine (2012)
-
Diabetes Drugs
Pharmaceutical Medicine (2011)
-
Quantitative assessment of the expanding complementarity between public and commercial databases of bioactive compounds
Journal of Cheminformatics (2009)